Nicolet Advisory Services LLC Has $1.15 Million Stake in Pfizer Inc. (NYSE:PFE)

Nicolet Advisory Services LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 1.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,498 shares of the biopharmaceutical company’s stock after purchasing an additional 451 shares during the period. Nicolet Advisory Services LLC’s holdings in Pfizer were worth $1,148,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. Leelyn Smith LLC raised its position in Pfizer by 7.0% in the 3rd quarter. Leelyn Smith LLC now owns 82,456 shares of the biopharmaceutical company’s stock worth $2,386,000 after purchasing an additional 5,382 shares during the last quarter. Stonebrook Private Inc. bought a new position in Pfizer during the 3rd quarter worth approximately $208,000. Meridian Wealth Management LLC bought a new stake in shares of Pfizer in the 3rd quarter valued at $2,651,000. Allen Capital Group LLC raised its position in shares of Pfizer by 9.1% during the third quarter. Allen Capital Group LLC now owns 113,921 shares of the biopharmaceutical company’s stock worth $3,297,000 after purchasing an additional 9,546 shares during the period. Finally, Asset Management Group Inc. increased its position in shares of Pfizer by 1.7% during the third quarter. Asset Management Group Inc. now owns 51,878 shares of the biopharmaceutical company’s stock worth $1,501,000 after acquiring an additional 875 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $25.63 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The business’s 50 day moving average price is $28.21 and its 200-day moving average price is $28.57. The firm has a market cap of $145.24 billion, a P/E ratio of 34.64, a P/E/G ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.17) EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company increased their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.